Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-11-21
2006-11-21
Schultz, James (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024500, C514S04400A, C435S006120, C435S325000, C435S375000
Reexamination Certificate
active
07138511
ABSTRACT:
In a preferred aspect of the invention, the upstream sequences of the TIGR protein encoding sequence can be used to diagnose a sensivity to steroids and a risk for glaucoma or ocular hypertensive disorders. Methods, kits, and nucleic acids containing polymorphisms, base substitutions, or base additions located within the upstream region and within protein-encoding regions of the TIGR gene are also provided. The upstream sequences disclosed, including the TIGR promoter regions and those regions possessing functional characterisitics associated with or possesssed by the TIGR gene 5′regulatory region, can also be used to generate cells, vectors, and nucleic acids useful in a variety of diagnostic and prognostic methods and kits as well as therapeutic compounds, compositions, and methods.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 3887699 (1975-06-01), Yolles
patent: 4582788 (1986-04-01), Erlich
patent: 4617299 (1986-10-01), Knepper
patent: 4683194 (1987-07-01), Saiki et al.
patent: 4683202 (1987-07-01), Mullis et al.
patent: 4757089 (1988-07-01), Epstein
patent: 4829088 (1989-05-01), Doulakas
patent: 4886743 (1989-12-01), Hood
patent: 5075217 (1991-12-01), Weber
patent: 5124154 (1992-06-01), Babcock et al.
patent: 5130238 (1992-07-01), Malek et al.
patent: 5169766 (1992-12-01), Schuster et al.
patent: 5175082 (1992-12-01), Jeffreys
patent: 5190762 (1993-03-01), Yarosh
patent: 5192535 (1993-03-01), Davis et al.
patent: 5270052 (1993-12-01), Callahan et al.
patent: 5420120 (1995-05-01), Boltralik
patent: 5474985 (1995-12-01), Polansky et al.
patent: 5516657 (1996-05-01), Murphy et al.
patent: 5582979 (1996-12-01), Weber
patent: 5599535 (1997-02-01), Polansky et al.
patent: 5606043 (1997-02-01), Nguyen et al.
patent: 5674888 (1997-10-01), Polansky et al.
patent: 5789169 (1998-08-01), Nguyen et al.
patent: 5849879 (1998-12-01), Nguyen et al.
patent: 5854415 (1998-12-01), Nguyen et al.
patent: 5861497 (1999-01-01), Nguyen et al.
patent: 5885776 (1999-03-01), Stone et al.
patent: 5916778 (1999-06-01), Stone
patent: 5925748 (1999-07-01), Stone
patent: 6075027 (2000-06-01), Chojkier et al.
patent: 6100035 (2000-08-01), Kauffman et al.
patent: 6150161 (2000-11-01), Nguyen et al.
patent: 6171788 (2001-01-01), Nguyen et al.
patent: 6248867 (2001-06-01), Nguyen et al.
patent: 6271026 (2001-08-01), Stone et al.
patent: 6342524 (2002-01-01), Hellberg et al.
patent: 6403307 (2002-06-01), Stone et al.
patent: 6475724 (2002-11-01), Nguyen et al.
patent: 6956103 (2005-10-01), Stone et al.
patent: 1176565 (1984-10-01), None
patent: 2216997 (1999-03-01), None
patent: 50424 (1982-04-01), None
patent: 58481 (1982-08-01), None
patent: 84796 (1983-08-01), None
patent: 158277 (1985-10-01), None
patent: 201184 (1986-12-01), None
patent: 237362 (1987-09-01), None
patent: 258017 (1988-03-01), None
patent: 0 329 822 (1989-08-01), None
patent: 370719 (1990-05-01), None
patent: 2135774 (1984-09-01), None
patent: WO 88/10315 (1988-12-01), None
patent: WO 89/06700 (1989-07-01), None
patent: WO 89/06964 (1989-08-01), None
patent: WO 90/01069 (1990-02-01), None
patent: WO 90/11369 (1990-10-01), None
patent: WO 90/13668 (1990-11-01), None
patent: WO 91/05771 (1991-05-01), None
patent: WO 92/13102 (1992-08-01), None
patent: WO 93/12234 (1993-06-01), None
patent: WO 94/04557 (1994-03-01), None
patent: WO 96/14411 (1996-05-01), None
patent: WO 96/33287 (1996-10-01), None
patent: WO 98/20131 (1998-05-01), None
patent: WO98/32850 (1998-07-01), None
patent: WO98/44107 (1998-10-01), None
patent: WO 98/44108 (1998-10-01), None
patent: WO 99/16898 (1999-04-01), None
patent: WO 00/42220 (2000-07-01), None
Escribano et al., GenBank, Accession No. AB006686 (1995).
W. French Anderson, Nature, vol. 392, Supp, Apr. 30, 1998, pp. 25-30.
Inder M. Verma et al., NATURE, vol. 389, pp. 239-242.
Becker 1986. Nature V. 324 18/25 pp. 686-688.
Nguyen et al. J. Biol. Chem. 1998. 273(11) 6341-6350.
Kubota R et al., “Genomic organisation of the human myocilin gene(MYOC)responsible for primary open angle glaucoma,” Biochemical and Biophysical Research Communications, US, Academic Press Inc., vol. 242, No. 242, 1998, pp. 396-400.
Anfossi, G. et al., “An Oligomer Complementary to c-myb-encoded mRNA Inhibits Proliferation of Human Myeloid Leukemia Cell Lines,” Proc. Natl. Acad. Sic. (USA) 86:3379 (1989).
Armour, J.A.L. et al., “Recent Advances in Minisatellite Biology,” FEBS Lett. 307:113-115 (1992).
Baldino, F. et al., “High-resolution in situ hybridization histochemistry,” Methods in Enzymology, 168:761-77 (1989).
Barany, F., “Genetic Disease Detection and DNA Amplification Using Cloned Thermostable Ligase,” Proc. Natl. Acad. Sci. (USA) 88:189-93 (1991).
Baumhueter et al., “A variant nuclear protein in dedifferentiated haptoma cells binds to the same functional sequences in the b fibrinogen gene bromoter as HNF-1,” EMBO J., 7(8):2485-93(1988).
Beato, “Gene regulation by steroid hormones,” Cell, 56:335-44 (1989).
Becker et al., “In Vivo protein—DNA interactions in a glucocorticoid response element require the presence of the hormone,” Nature, 324:686-88 (1986).
Becker, D., et al., “Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basibroblast growth factor,” EMBO J. 8:3685-91 (1989).
Bengtsson, B., “Incidence of manifest glaucoma,” Br. J. Ophthalmol. 73:483-87 (1989).
Botstein, D. et al., “Construction of a genetic linkage man using restriction fragment length polymorphisms,” Amn. J. Hum. Genet. 32:314-331 (1980).
Brent, “Mutations of the rat growth hormone promoter which invrease and decrease response to thyroid hormone define a consensus thyroid hormone response element,” Molecular Endocrinology, 3:1996-2004 (1989).
Breslauer, K. et al. “Predicting DNA duplex stability from the base sequence,” Proc. Natl. Acad. Sci. USA 83:3746-50 (1986).
Chen et al., “Identification of a TIGR Promoter Sequence Variant, TIGR.mt1, in a POAG Pedigree and Estimation of its Frequency in Adult POAG,” Abstract #3156, Association for Research in Vision and Ophthalmology Meeting (1998).
Chen et al., “Identification of a TIGR Promoter Sequence Variantin Steroid Responders and Evidence for a Glucocorticoid-induced DNA Binding Protein of the TIGR Gene in TM Cells” Abstract #2666, Association for Research in Vision and Ophthalmology Meeting (1999).
Chen, P. “Expression of Trabecular Meshwork Inducible Glucocorticoid Response (TIGR) peptide in SF9 Cells,” Invest. Opthal. Vis. Sci. 34(4) 1385 Abstract (1993).
Chodosh et al., “Human CCAAT-Binding Proteins have heterologous subunits,” Cell, 53:11-24 (1988).
Clark, A.F., “Evaluation of anti-glaucoma compounds and discovery of pathogenic mechanisms using perfusion cultured human eyes” Exper. Eye Res. 55:265 Abstract (1992).
Claverie et al., “Alu Alert,” Nature 371: 751-52 (1994).
Coles et al., “An H1 histone gene-specific 5′ element and evolution of H1 and H5 genes,” Nucleic Acids Research, 13:585-94 (1985).
Comb et al., “CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2,” Nucleic Acids Research, 18:3975-82 (1990).
Courtois et al., “Nuclear factor-1 and activator protein-2 bind in a mutually exclusive way to overlapping promoter sequences and trans-activate the human growth hormone gene,” Nucleic Acids Research, 18:57-64 (1990).
deVerneuil et al., “The lack of transcriptional activation of the v-erb A oncogene is in part due to a mutation present in the DNA binding domain of the protein,” Nucleic Acids Research, 18:4489-97 (1990).
deWet et al., “Firefly luciferase gene: structure and expression in mammalian cells,” Molecular and Cellular Biology, 7:725-37 (1987).
Escribano, J. et al., “Isolation and Characterization of Cell-Specific cDNA Clones fro
Chen Hua
Chen Pu
Nguyen Thai D.
Polansky Jon R.
Schultz James
The Regents of the University of California
LandOfFree
Nucleic acids, kits and methods for the diagnosis, prognosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids, kits and methods for the diagnosis, prognosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids, kits and methods for the diagnosis, prognosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682128